Results 171 to 180 of about 195,924 (307)

Predictors of disease-free and overall survival in retroperitoneal sarcomas: A modern 16-year multi-institutional study from the United States Sarcoma Collaboration (USSC) [PDF]

, 2019
al., et, Fields, Ryan C., Krasnick, Bradley A.   +2 more
core   +1 more source

The impact of time‐to‐recurrence on post‐recurrence mortality in stage I–III colorectal cancer: A nationwide Danish cohort study

International Journal of Cancer, EarlyView.
What's New? Colorectal cancer (CRC) recurrence is a significant threat to survival despite surgery with curative intent. The characteristics of CRC recurrence, however, remain poorly understood, challenging postoperative surveillance. This study investigated post‐recurrence mortality and associations between time‐to‐recurrence and mortality among stage
Jesper Nors, Kåre Andersson Gotschalck, Rune Erichsen, Claus Lindbjerg Andersen   +3 more
wiley   +1 more source

Neoadjuvant therapy in resectable and borderline resectable pancreatic cancer-safe but standard of care? [PDF]

Gland Surg
Lee JJ, Desai CS, Kim HJ.
europepmc   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia, Anne‐Sophie van der Werf‐'t Lam, Madalina Cabuta, Maartje Nielsen, Noah C. Helderman   +4 more
wiley   +1 more source

Surgical Perspectives on Neoadjuvant Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. [PDF]

Cancers (Basel)
Zhang J, Geng M, Friess H, Demir IE, Scheufele F.   +4 more
europepmc   +1 more source

Adherens junction protein expression is associated with poor response to neoadjuvant FLOT chemotherapy and pro‐inflammatory tumor microenvironment in esophageal adenocarcinoma

International Journal of Cancer, EarlyView.
What's New? Esophageal adenocarcinoma (EAC) is an aggressive cancer with poor survival and variable response to perioperative chemotherapy. Although histopathological features correlate with outcomes, the relationship specifically between adherens junction (AJ) protein expression and treatment response in EAC remains uncertain.
Bastian Grothey, Heike Löser, Tillmann Bedau, Wolfgang Schröder, Christiane J. Bruns, Thomas Zander, Max Krämer, Reinhard Büttner, Alexander Quaas   +8 more
wiley   +1 more source

Risk factors for distant recurrence in patients with rectal cancer supporting selection for total neoadjuvant therapy. [PDF]

Acta Oncol
Slipsager AB, Bahij R, Christensen HS, Diness LV, Havelund BM, Ramlov A, Skriver SK, Szpejewska JE, Tcacenco O, Thomsen C, Poulsen LØ.   +10 more
europepmc   +1 more source

Intensity modulated radiation therapy for squamous cell carcinoma of the vulva: Treatment technique and outcomes [PDF]

, 2017
Chundury, Anupama, DeWees, Todd, Grigsby, Perry W, Hassanzadeh, Comron, Mullen, Daniel, Mutch, David G, Powell, Matthew A, Rao, Yuan James, Schwarz, Julie K   +8 more
core   +2 more sources

Coronavirus disease 2019 infection reduces EGFR‐TKI efficacy in non‐small cell lung carcinoma: Real‐world evidence from a multicenter propensity‐matched cohort

International Journal of Cancer, EarlyView.
What's New? Lung cancer patients with COVID‐19 experience significantly increased risk for severe illness and mortality. However, research addressing the effect of COVID‐19 on non‐small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) remains unknown.
Wenjie Tang, Xiaoxuan Hou, Li Li, Hanxi Zhao, Xiaoyong Tang, Wanqi Zhu, Xiaohui Yan, Jing Liu, Qian Wu, Zhu Qiao, Shanliang Hu, Mingwei Zhang, Xiaolin Li, Peng Xie   +13 more
wiley   +1 more source

Evaluating the prognostic significance of HIST1H4C in breast cancer: implications for neoadjuvant therapy. [PDF]

Sci Rep
Qian L, Ge R, Haihu Z, Cairong Z, Yuanxuan C, Yongdong L, Xiaofeng Z, Jingjing L, Xuan Y, Kai C, Jie L.   +10 more
europepmc   +1 more source